- Home
- URGN vs DIN Comparison
URGN vs DIN Comparison
Compare URGN & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- DIN
- Stock Information
- Founded
- URGN 2004
- DIN 1958
- Country
- URGN United States
- DIN United States
- Employees
- URGN N/A
- DIN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- DIN Restaurants
- Sector
- URGN Health Care
- DIN Consumer Discretionary
- Exchange
- URGN Nasdaq
- DIN Nasdaq
- Market Cap
- URGN 547.1M
- DIN 494.3M
- IPO Year
- URGN 2017
- DIN 1991
- Fundamental
- Price
- URGN $11.33
- DIN $30.92
- Analyst Decision
- URGN Strong Buy
- DIN Buy
- Analyst Count
- URGN 5
- DIN 8
- Target Price
- URGN $44.50
- DIN $40.83
- AVG Volume (30 Days)
- URGN 351.4K
- DIN 432.2K
- Earning Date
- URGN 11-06-2024
- DIN 11-06-2024
- Dividend Yield
- URGN N/A
- DIN 6.59%
- EPS Growth
- URGN N/A
- DIN 25.34
- EPS
- URGN N/A
- DIN 6.02
- Revenue
- URGN $89,363,000.00
- DIN $813,838,000.00
- Revenue This Year
- URGN $13.39
- DIN N/A
- Revenue Next Year
- URGN $45.06
- DIN $0.65
- P/E Ratio
- URGN N/A
- DIN $5.13
- Revenue Growth
- URGN 15.64
- DIN N/A
- 52 Week Low
- URGN $10.60
- DIN $28.25
- 52 Week High
- URGN $20.70
- DIN $51.35
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- DIN 40.62
- Support Level
- URGN $11.10
- DIN $30.87
- Resistance Level
- URGN $13.13
- DIN $32.05
- Average True Range (ATR)
- URGN 0.53
- DIN 1.31
- MACD
- URGN -0.10
- DIN -0.40
- Stochastic Oscillator
- URGN 12.15
- DIN 3.06
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.